$149 or $449. Same drug. Your move.
We price 12 GLP-1 programmes on what they bill, not what they advertise — and publish the gap between the two.
DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.
Tirzepatide, cheapest first
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $149 | $199 | +$50 | — |
| Zealthy | $216 | $216 | none | +$17/mo |
| Hims & Hers | $199 | $238 | +$39 | +$39/mo |
| Mochi Health | $199 | $278 | +$79 | +$79/mo |
| Eden | $199 | $298 | +$99 | +$99/mo |
| TrimRx | $349 | $399 | +$50 | +$200/mo |
| MEDVi | $399 | $399 | none | +$200/mo |
Semaglutide, cheapest first
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $99 | $149 | +$50 | — |
| Zealthy | $151 | $151 | none | +$2/mo |
| Mochi Health | $99 | $178 | +$79 | +$29/mo |
| Hims & Hers | $79 | $188 | +$109 | +$39/mo |
| Eden | $99 | $198 | +$99 | +$49/mo |
| Henry Meds | $179 | $297 | +$118 | +$148/mo |
| Ro | $149 | $448 | +$299 | +$299/mo |
Rankings
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
- Where the traps are
The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.
- Best value on the board
Cheapest is one question. Best value — where the money buys something — is another.
Briefings
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- The compounding rules
Cheap GLP-1s exist because of compounding. The FDA moved against it again in April. What that means for the board.
- Tirzepatide vs semaglutide
A head-to-head trial settled the results question. The price question goes the other way.
Read this bit. Everything on this board under about $300 a month is a compounded preparation, which is not FDA-approved — and the FDA moved against compounded GLP-1s again in April 2026. What that does to these prices →
Board verified 2026-09-18